Literature DB >> 18163957

Correlation between expression of DcR3 on tumor cells and sensitivity to FasL.

Wenzhu Li1, Changgong Zhang, Caixia Chen, Guohong Zhuang.   

Abstract

To investigate the correlation between sensitivity to Fas ligand (FasL) and expression level of decoy receptor 3 (DcR3) on tumor cell surface, Fas/DcR3 mRNA expression was detected by RT-PCR. Anti-DcR3 mAb was used to detect expression level of DcR3 on surface of tumor cells by flow cytometry. Caspase-8, caspase-9, caspase-3, Bcl-2 expressions were analyzed by Western blot, respectively. Sensitivity to apoptosis induced by FasL was determined by Annexin V apoptosis kit. The expressions of DcR3 on the surface of tumor cells from high to low were approximately 35.3% in BGC823 cells, and 21.6% in MCF-7 cells, respectively. The apoptotic rates induced by FasL from low to high were 15.6% in BGC823 cells, and 58.2% in MCF-7 cells, respectively. There was a significant correlation between the expression levels of DcR3 with FasL-inducing apoptosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18163957

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  12 in total

1.  Aberrant expression and function of death receptor-3 and death decoy receptor-3 in human cancer.

Authors:  Zhicheng Ge; Andrew J Sanders; Lin Ye; Wen G Jiang
Journal:  Exp Ther Med       Date:  2011-01-20       Impact factor: 2.447

2.  A shear stress responsive gene product PP1201 protects against Fas-mediated apoptosis by reducing Fas expression on the cell surface.

Authors:  Sudhanshu Shukla; Ken-ichi Fujita; Qi Xiao; Zhiyong Liao; Susan Garfield; Srinivasa M Srinivasula
Journal:  Apoptosis       Date:  2011-02       Impact factor: 4.677

3.  MMP-2 and DcR3 expression in esophageal cancer tissue and correlation with patient survival.

Authors:  Ran Ao; Ya-Qi Du; Ying Wang; Yu-Shuai Chen; Bing-Yuan Wang
Journal:  Int J Clin Exp Med       Date:  2013-09-01

4.  The detection, treatment, and biology of epithelial ovarian cancer.

Authors:  Jennifer Aa Gubbels; Nick Claussen; Arvinder K Kapur; Joseph P Connor; Manish S Patankar
Journal:  J Ovarian Res       Date:  2010-03-29       Impact factor: 4.234

5.  Combined treatment with denbinobin and Fas ligand has a synergistic cytotoxic effect in human pancreatic adenocarcinoma BxPC-3 cells.

Authors:  C R Yang; J H Guh; C M Teng; C C Chen; P H Chen
Journal:  Br J Pharmacol       Date:  2009-05-18       Impact factor: 8.739

6.  Idiopathic pulmonary fibrosis fibroblasts become resistant to Fas ligand-dependent apoptosis via the alteration of decoy receptor 3.

Authors:  Jintaek Im; Kyutae Kim; Polla Hergert; Richard Seonghun Nho
Journal:  J Pathol       Date:  2016-07-14       Impact factor: 7.996

7.  Elevated Serum Levels of the Antiapoptotic Protein Decoy-Receptor 3 Are Associated with Advanced Liver Disease.

Authors:  Giorgos Bamias; Michalis Gizis; Ioanna Delladetsima; Eyfrosyni Laoudi; Spyros I Siakavellas; Ioannis Koutsounas; Garyfallia Kaltsa; John Vlachogiannakos; Irene Vafiadis-Zouboulis; George L Daikos; George V Papatheodoridis; Spiros D Ladas
Journal:  Can J Gastroenterol Hepatol       Date:  2016-08-09

8.  Decoy receptor 3 (DcR3) overexpression predicts the prognosis and pN2 in pancreatic head carcinoma.

Authors:  Jian Zhou; Shiduo Song; Dechun Li; Songbing He; Bing Zhang; Zhenxin Wang; Xinguo Zhu
Journal:  World J Surg Oncol       Date:  2014-03-05       Impact factor: 2.754

9.  Expression and clinicopathological implication of DcR3 in lung cancer tissues: a tissue microarray study with 365 cases.

Authors:  Yu Zhang; Jie Luo; Rongquan He; Wenting Huang; Zuyun Li; Ping Li; Yiwu Dang; Gang Chen; Shikang Li
Journal:  Onco Targets Ther       Date:  2016-08-10       Impact factor: 4.147

10.  The siRNA silencing of DcR3 expression induces Fas ligand-mediated apoptosis in HepG2 cells.

Authors:  Tuanjie Zhao; Yingchen Xu; Shulin Ren; Chaojie Liang; Xiaona Zhou; Jixiang Wu
Journal:  Exp Ther Med       Date:  2018-03-19       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.